Insights

Archer Materials (ASX:AXE) share price leaps 4% on biochip update

What news did the company announce to the ASX today?
The post Archer Materials (ASX:AXE) share price leaps 4% on biochip update appeared first on The Motley Fool Australia. –

The Archer Materials Ltd (ASX: AXE) share price was charging ahead today following a technical progress update on the company’s biochip.

At market close, the Archer share price was 4.9% higher at $1.285.

Archer progresses biochip development

Investors were driving up the Archer share price today after the materials technology company announced a major breakthrough with its biochip technology.

In a release, Archer advises it has developed its first biochemical reactions for detecting nucleic acid sequences. This allows small droplets of biological samples to be processed and analysed using special sensor devices integrated within the biochip.

Nucleic acid markers are useful for monitoring a person’s health and determining if a disease is present. Commonly known techniques to analyse biological samples for nucleic acids include polymerase chain reaction (PCR). The techniques developed by Archer have special significance because COVID-19 is detected through PCR testing.

Last month, the company used advanced fabrication techniques to achieve features like hair-thin microfluidic channels. To put this in perspective, these channels are less than 20 micrometres in width (about 3x thinner than human hair).

The channels enable sample processing as well as transportation into smaller built-in sensors for analysing biochemical targets.

The latest development marks another milestone in Archer’s pursuit of commercialising its biochip technology.

Best-in-class capabilities in nanofabrication is a global competitive advantage in the multibillion-dollar point of care medical diagnostics industry. There are few companies developing and commercialising biochips because it’s difficult to achieve precision engineering at the nano scale.

What did Archer management say?

Archer CEO Dr Mohammad Choucair commented:

This is a significant achievement, as the Company has now, with its in-house capability, developed the biochemical foundations to potentially allow for future operations and applications of Archer’s biochip in the detection of various diseases.

There are few examples of lab-on-a-chip technologies that detect nucleic acids without the need for PCR. Archer’s biochemical processes could potentially allow for on-chip detection of pathogens, with several practical advantages, including eliminating cold-logistics supply chain requirements and the need for PCR, if favourable.

About the Archer share price

The Archer share price has surged by 138% in the past 12 months. However, the company’s shares are still more than 50% off their all-time high of $3.08 reached in mid-August.

Based on valuation grounds, Archer presides a market capitalisation of $318 million, with 247 million shares on issue.

The post Archer Materials (ASX:AXE) share price leaps 4% on biochip update appeared first on The Motley Fool Australia.

Should you invest $1,000 in Archer right now?

Before you consider Archer, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Archer wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why the Archer Materials (ASX:AXE) share price is charging 5% higher

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!